These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 21393205)
1. Clinical experience with daptomycin in Europe: the first 2.5 years. Gonzalez-Ruiz A; Beiras-Fernandez A; Lehmkuhl H; Seaton RA; Loeffler J; Chaves RL J Antimicrob Chemother; 2011 Apr; 66(4):912-9. PubMed ID: 21393205 [TBL] [Abstract][Full Text] [Related]
2. Brazilian experience in EU-CORE: daptomycin registry and treatment of serious Gram-positive infections. Timerman A; Brites C; Bicudo E; Grinbaum RS; Costa Filho R; Carrilho CD; Bichels A; Barreto T Braz J Infect Dis; 2013; 17(6):647-53. PubMed ID: 23916455 [TBL] [Abstract][Full Text] [Related]
3. Daptomycin in the Clinical Setting: 8-Year Experience with Gram-positive Bacterial Infections from the EU-CORE(SM) Registry. Gonzalez-Ruiz A; Gargalianos-Kakolyris P; Timerman A; Sarma J; José González Ramallo V; Bouylout K; Trostmann U; Pathan R; Hamed K Adv Ther; 2015 Jun; 32(6):496-509. PubMed ID: 26108157 [TBL] [Abstract][Full Text] [Related]
4. Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE. Seaton RA; Gonzalez-Ruiz A; Cleveland KO; Couch KA; Pathan R; Hamed K Ann Clin Microbiol Antimicrob; 2016 Mar; 15():18. PubMed ID: 26976128 [TBL] [Abstract][Full Text] [Related]
5. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE). Mohr JF; Friedrich LV; Yankelev S; Lamp KC Int J Antimicrob Agents; 2009 Jun; 33(6):543-8. PubMed ID: 19201165 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of Effectiveness and Safety of High-Dose Daptomycin: Results from Patients Included in the European Cubicin(®) Outcomes Registry and Experience. Seaton RA; Menichetti F; Dalekos G; Beiras-Fernandez A; Nacinovich F; Pathan R; Hamed K Adv Ther; 2015 Dec; 32(12):1192-205. PubMed ID: 26610384 [TBL] [Abstract][Full Text] [Related]
7. Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy. Moise PA; Hershberger E; Amodio-Groton MI; Lamp KC Ann Pharmacother; 2009 Jul; 43(7):1211-9. PubMed ID: 19584384 [TBL] [Abstract][Full Text] [Related]
8. Clinical Experience with Daptomycin for the Treatment of Gram-positive Infections in Children and Adolescents. Syriopoulou V; Dailiana Z; Dmitriy N; Utili R; Pathan R; Hamed K Pediatr Infect Dis J; 2016 May; 35(5):511-6. PubMed ID: 26849158 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of daptomycin in complicated skin and soft-tissue infections and bacteraemia in clinical practice: results of a large non-interventional study. Gonzalez-Ruiz A; Beiras-Fernandez A; Lehmkuhl H; Dohmen PM; Loeffler J; Chaves RL Int J Antimicrob Agents; 2013 Apr; 41(4):372-8. PubMed ID: 23499225 [TBL] [Abstract][Full Text] [Related]
10. [Antibiotic treatment of enterococcal infections in gastroenterology with daptomycin - first experiences from the EU-CORE registry study (European Cubicin® Outcomes Registry and Experience)]. Lübbert C; Wilhelms D; Worlitzsch D; Ettrich TJ; Behl S; Seufferlein T Z Gastroenterol; 2012 Apr; 50(4):373-81. PubMed ID: 22430297 [TBL] [Abstract][Full Text] [Related]
11. Daptomycin use in neutropenic patients with documented gram-positive infections. Rolston KV; Besece D; Lamp KC; Yoon M; McConnell SA; White P Support Care Cancer; 2014 Jan; 22(1):7-14. PubMed ID: 23975231 [TBL] [Abstract][Full Text] [Related]
12. Daptomycin for the treatment of infective endocarditis: results from a European registry. Dohmen PM; Guleri A; Capone A; Utili R; Seaton RA; González-Ramallo VJ; Pathan R; Heep M; Chaves RL J Antimicrob Chemother; 2013 Apr; 68(4):936-42. PubMed ID: 23190763 [TBL] [Abstract][Full Text] [Related]
13. Daptomycin treatment in Gram-positive vascular graft infections. Arnaiz de Las Revillas F; Fernandez-Sampedro M; Arnaiz-García AM; Gutierrez-Cuadra M; Armiñanzas C; Pulitani I; Ponton A; Tascon V; García I; Fariñas MC Int J Infect Dis; 2018 Mar; 68():69-73. PubMed ID: 29373845 [TBL] [Abstract][Full Text] [Related]
14. Daptomycin use in patients with osteomyelitis: a preliminary report from the EU-CORE(SM) database. Seaton RA; Malizos KN; Viale P; Gargalianos-Kakolyris P; Santantonio T; Petrelli E; Pathan R; Heep M; Chaves RL J Antimicrob Chemother; 2013 Jul; 68(7):1642-9. PubMed ID: 23515247 [TBL] [Abstract][Full Text] [Related]
17. Daptomycin experience in critical care patients: results from a registry. Brown JE; Fominaya C; Christensen KJ; McConnell SA; Lamp KC Ann Pharmacother; 2012 Apr; 46(4):495-502. PubMed ID: 22454446 [TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience. Sakoulas G; Brown J; Lamp KC; Friedrich LV; Lindfield KC Clin Ther; 2009 Sep; 31(9):1936-45. PubMed ID: 19843483 [TBL] [Abstract][Full Text] [Related]
19. Multicenter study of high-dose daptomycin for treatment of enterococcal infections. Casapao AM; Kullar R; Davis SL; Levine DP; Zhao JJ; Potoski BA; Goff DA; Crank CW; Segreti J; Sakoulas G; Cosgrove SE; Rybak MJ Antimicrob Agents Chemother; 2013 Sep; 57(9):4190-6. PubMed ID: 23774437 [TBL] [Abstract][Full Text] [Related]
20. Daptomycin for the treatment of osteomyelitis and orthopaedic device infections: real-world clinical experience from a European registry. Malizos K; Sarma J; Seaton RA; Militz M; Menichetti F; Riccio G; Gaudias J; Trostmann U; Pathan R; Hamed K Eur J Clin Microbiol Infect Dis; 2016 Jan; 35(1):111-8. PubMed ID: 26563898 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]